Effective anti-Alzheimer Ab therapy involves depletion of specific Ab oligomer subtypes

Neurology: Neuroimmunology and NeuroInflammation

Volumn 3, Issue 3, 2016, Pages

  Knight, Elysse M ^a   Kim, Soong Ho ^a   Kottwitz, Jessica C ^a   Hatami, Asa ^b   Albay, Ricardo ^b   Suzuki, Akinobu ^c   Lublin, Alex ^a   Alberini, Cristina M ^d   Klein, William L ^e   Szabo, Paul ^f   Relkin, Norman R ^f   Ehrlich, Michelle ^a   Glabe, Charles G ^b   Gandy, Sam ^a,g   Steele, John W ^a,h  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^c UNIVERSITY OF TOYAMA   (Japan)

^d NEW YORK UNIVERSITY   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f FEIL FAMILY BRAIN AND MIND RESEARCH INSTITUTE   (United States)

^g VETERANS AFFAIRS MEDICAL CENTER   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

A11 SOLUBLE AMYLOID BETA PROTEIN; AMYLOID BETA OLIGOMER PROTEIN; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; IMMUNOGLOBULIN; NU4 SOLUBLE AMYLOID BETA PROTEIN; OC TYPE FABRILLAR AMYLOID BETA OLIGOMER PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; IMMUNOREACTIVITY; MEMORY DISORDER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN DEPLETION; PROTEIN TARGETING;

EID: 84994337754     PISSN: None     EISSN: 23327812     Source Type: Journal    
DOI: 10.1212/NXI.0000000000000237     Document Type: Article

References (40)

1. Gandy S. Lifelong management of amyloid-beta metabolism to prevent Alzheimer's disease. N Engl J Med 2012; 367:864-866.
2. Gandy S, Sano M. Alzheimer disease: solanezumab- prospects for meaningful interventions in AD? Nat Rev Neurol 2015;11:669-670.
3. Knight EM, Gandy S. Immunomodulation and AD: down but not out. J Clin Immunol 2014;34(suppl 1):S70-S73.
4. Dodel R, Hampel H, Depboylu C, et al. Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease. Ann Neurol 2002;52:253-256.
5. Szabo P, Relkin N, Weksler ME. Natural human antibodies to amyloid beta peptide. Autoimmun Rev 2008; 7:415-420.
6. Weksler ME, Relkin N, Turkenich R, LaRusse S, Zhou L, Szabo P. Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Exp Gerontol 2002; 37:943-948.
7. Relkin N. Intravenous immunoglobulin for Alzheimer's disease. Clin Exp Immunol 2014;178(suppl 1):27-29.
8. Magga J, Puli L, Pihlaja R, et al. Human intravenous immunoglobulin provides protection against Ab toxicity by multiple mechanisms in a mouse model of Alzheimer's disease. J Neuroinflammation 2010;7:90.
9. Puli L, Pomeshchik Y, Olas K, Malm T, Koistinaho J, Tanila H. Effects of human intravenous immunoglobulin on amyloid pathology and neuroinflammation in a mouse model of Alzheimer's disease. J Neuroinflammation 2012; 9:105.
10. Relkin NR, Szabo P, Adamiak B, et al. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging 2009;30:1728-1736.
11. Tsakanikas D, Shah K, Flores C, Assuras S, Relkin NR. P4-351: effects of uninterrrupted intravenous immunoglobulin treatment of Alzheimer's disease for nine months. Alzheimers Dement 2008;4:T776.
12. Gandy S, Simon AJ, Steele JW, et al. Days to criterion as an indicator of toxicity associated with human Alzheimer amyloid-beta oligomers. Ann Neurol 2010;68:220-230.
13. Barghorn S, Nimmrich V, Striebinger A, et al. Globular amyloid beta-peptide oligomer: a homogenous and stable neuropathological protein in Alzheimer's disease. J Neurochem 2005;95:834-847.
14. O'Nuallain B, Wetzel R. Conformational Abs recognizing a generic amyloid fibril epitope. Proc Natl Acad Sci USA 2002;99:1485-1490.
15. O'Nuallain B, Williams AD, Westermark P, Wetzel R. Seeding specificity in amyloid growth induced by heterologous fibrils. J Biol Chem 2004;279:17490-17499.
16. Szabo P, Mujalli DM, Rotondi ML, et al. Measurement of anti-beta amyloid antibodies in human blood. J Neuroimmunol 2010;227:167-174.
17. Knight EM, Williams HN, Stevens AC, et al. Evidence that small molecule enhancement of beta-hexosaminidase activity corrects the behavioral phenotype in Dutch APP (E693Q) mice through reduction of ganglioside-bound Abeta. Mol Psychiatry 2015;20:109-117.
18. Knight EM, Martins IV, Gumusgoz S, Allan SM, Lawrence CB. High-fat diet-induced memory impairment in triple-transgenic Alzheimer's disease (3xTgAD) mice is independent of changes in amyloid and tau pathology. Neurobiol Aging 2014;35:1821-1832.
19. Steele JW, Lachenmayer ML, Ju S, et al. Latrepirdine improves cognition and arrests progression of neuropathology in an Alzheimer's mouse model. Mol Psychiatry 2013; 18:889-897.
20. Jacobsen JS, Wu CC, Redwine JM, et al. Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2006;103:5161-5166.
21. Laczo J, Vlcek K, Vyhnalek M, et al. Spatial navigation testing discriminates two types of amnestic mild cognitive impairment. Behav Brain Res 2009;202:252-259.
22. Gandy S, Zhang YW, Ikin A, et al. Alzheimer's presenilin 1 modulates sorting of APP and its carboxyl-terminal fragments in cerebral neurons in vivo. J Neurochem 2007;102:619-626.
23. Kim SH, Steele JW, Lee SW, et al. Proneurogenic group II mGluR antagonist improves learning and reduces anxiety in Alzheimer Abeta oligomer mouse. Mol Psychiatry 2014; 19:1235-1242.
24. Wu JW, Breydo L, Isas JM, et al. Fibrillar oligomers nucleate the oligomerization of monomeric amyloid beta but do not seed fibril formation. J Biol Chem 2010;285:6071-6079.
25. Tomic JL, Pensalfini A, Head E, Glabe CG. Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction. Neurobiol Dis 2009;35:352-358.
26. Liu P, Reed MN, Kotilinek LA, et al. Quaternary structure defines a large class of amyloid-beta oligomers neutralized by sequestration. Cell Rep 2015;11:1760-1771.
27. Scholl M, Wall A, Thordardottir S, et al. Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers. Neurology 2012;79:229-236.
28. Readhead B, Haure-Mirande JV, Zhang B, et al. Molecular systems evaluation of oligomerogenic APP and fibrillogenic APP/PSEN1 mouse models identifies shared features with human Alzheimer's brain molecular pathology. Mol Psychiatry Epub 2016 Jan 19.
29. Lopez-Gonzalez I, Schluter A, Aso E, et al. Neuroinflammatory signals in Alzheimer disease and APP/PS1 transgenic mice: correlations with plaques, tangles, and oligomeric species. J Neuropathol Exp Neurol 2015;74:319-344.
30. Dodel R, Balakrishnan K, Keyvani K, et al. Naturally occurring autoantibodies against beta-amyloid: investigating their role in transgenic animal and in vitro models of Alzheimer's disease. J Neurosci 2011;31:5847-5854.
31. Gong B, Pan Y, Zhao W, et al. IVIG immunotherapy protects against synaptic dysfunction in Alzheimer's disease through complement anaphylatoxin C5a-mediated AMPA-CREB-C/EBP signaling pathway. Mol Immunol 2013;56:619-629.
32. Klaver AC, Finke JM, Digambaranath J, Balasubramaniam M, Loeffler DA. Antibody concentrations to Abeta1-42 monomer and soluble oligomers in untreated and antibody-antigendissociated intravenous immunoglobulin preparations. Int Immunopharmacol 2010;10:115-119.
33. Istrin G, Bosis E, Solomon B. Intravenous immunoglobulin enhances the clearance of fibrillar amyloid-beta peptide. J Neurosci Res 2006;84:434-443.
34. St-Amour I, Pare I, Tremblay C, Coulombe K, Bazin R, Calon F. IVIg protects the 3xTg-AD mouse model of Alzheimer's disease from memory deficit and Abeta pathology. J Neuroinflammation 2014;11:54.
35. Liu YH, Bu XL, Liang CR, et al. An N-terminal antibody promotes the transformation of amyloid fibrils into oligomers and enhances the neurotoxicity of amyloidbeta: the dust-raising effect. J Neuroinflammation 2015; 12:153.
36. Solomon B, Koppel R, Frankel D, Hanan-Aharon E. Disaggregation of Alzheimer beta-amyloid by site-directed mAb. Proc Natl Acad Sci USA 1997;94:4109-4112.
37. Relkin N. Clinical trials of intravenous immunoglobulin for Alzheimer's disease. J Clin Immunol 2014;34(suppl 1): S74-S79.
38. Hatami A, Albay R III, Monjazeb S, Milton S, Glabe C. Monoclonal antibodies against Abeta42 fibrils distinguish multiple aggregation state polymorphisms in vitro and in Alzheimer disease brain. J Biol Chem 2014;289: 32131-32143.
39. Lambert MP, Velasco PT, Chang L, et al. Monoclonal antibodies that target pathological assemblies of Abeta. J Neurochem 2007;100:23-35.
40. Kayed R, Head E, Thompson JL, et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003;300:486-489.